Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02796352 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
A Phase 2 study, sponsored by Ahmad Tarhini.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02796352: Clinical Trial Phase 2 study, sponsored by Ahmad Tarhini.
NCT02796352 is a Phase 2 study that was terminated before completion, run by Ahmad Tarhini. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02796352, a Phase 2 study, was terminated before completion, sponsored by Ahmad Tarhini.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study is for patients with advanced stage III or stage IV melanoma not adequately treated by surgery who have progressed after treatment with nivolumab or pembrolizumab. The purpose of this study is to see if giving high dose interleukin-2 (IL-2) after progression on nivolumab or pembrolizumab is effective in treating metastatic melanoma. This study is also being done to look at the severity of side effects of IL-2 in patients. IL-2 is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced melanoma.
Primary Outcome
Percentage of complete responses (CR) plus partial responses (PR), based upon Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1
Interventions
- DRUG High dose bolus interleukin-2 (HD IL2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-04 |
| Phase | Phase 2 |
Why NCT02796352 stopped before completion
NCT02796352 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which High dose bolus interleukin-2 (HD IL2) is the first listed.
NCT02796352 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02796352 about?
NCT02796352 is a clinical study titled "A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study". This study is for patients with advanced stage III or stage IV melanoma not adequately treated by surgery who have progressed after treatment with nivolumab or pembrolizumab. The purpose of this study is to see if giving high dose interleukin-2 (IL-2) after progression on nivolumab or pembrolizumab ...
What is the current status of trial NCT02796352?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-09. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02796352?
The interventions under investigation include: High dose bolus interleukin-2 (HD IL2) (DRUG).
Who is sponsoring clinical trial NCT02796352?
This trial is sponsored by Ahmad Tarhini, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02796352's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia